Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic soli

Primary tabs

field_vote: 
Average: 9 (1 vote)
Publication type: 
Number of included patients: 
References: 
Therapeutic intervention: 
Therapeutic Substance(s): 

Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):259-62.
Total
pineal endocrine substitution therapy (TPEST) as a new neuroendocrine
palliative treatment of untreatable metastatic solid tumor patients: a
phase II study.

Lissoni P, Malugani F, Brivio F, Piazza A, Vintimilla C, Giani L, Tancini G.
Division of Radiation Oncology, S. Gerardo Hospital, Monza (Milan), Italy.
OBJECTIVES:
It is known since many years that the pineal gland plays an anticancer
role, and melatonin (MLT), the most investigated pineal hormone, has
been proven to exert antitumor activity. However, MLT would not be the
only hormone responsible for the antitumor action of the pineal gland.
In fact, recent advances in the pineal investigations have shown that
pineal indoles other than MLT may also exert anticancer activity,
namely the three main indoles, consisting of 5-methoxytriptamine
(5-MTT), 5-methoxytryptophol (5-MTP) and 5-methoxy-indole acetic acid
(5-MIA). Cancer progression has appeared to be associated with a
concomitant decline in the pineal endocrine function. Therefore, the
replacement of a complete pineal function in the advanced cancer
patients would require the exogenous administration of the overall four
pineal indoles. Several clinical studies have shown that MLT alone at
pharmacological doses may induce a control of the neoplastic
progression in about 30% of untreatable metastatic solid tumor
patients. The present study was performed in an attempt to evaluate the
therapeutic of a total pineal endocrine substitution therapy with its
four indole hormones in cancer patients, for whom no other conventional
therapy was available.
 
METHODS: The study included 14 metastatic solid
tumor patients, who had failed to respond to the conventional
anticancer therapies. The pineal indoles were given orally according to
a schedule elaborated in an attempt to reproduce their physiological
circadian secretion during the daily photoperiod. MLT was given at 20
mg/day during the night, whereas the other indoles were given at 1
mg/day, by administering 5-MIA in the morning, 5-MTP at noon and 5-MTT
in the afternoon. RESULTS: A disease-control was achieved in 9/14 (64%)
patients, consisting of partial response (PR) in one patient and stable
disease (SD) in the other 8 patients. The median time of
disease-control (PR + SD) was 6 months (range: 4-10). CONCLUSIONS: This
preliminary study shows that a total pineal endocrine replacement
therapy by an exogenous administration of the overall four pineal
indoles may induce a disease-control in about 60% of untreatable
metastatic solid tumor patients. Then, these results would be clearly
superior with respect to those described with MLT alone, by confirming
in humans that MLT is not the only hormone responsible for the
anticancer property of the pineal gland. Since Cartesius was the first
author who suggested the fundamental role of the pineal in the
connection between consciousness and biological life, this therapy
could be defined as a Cartesian therapy.